Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 305 Carcinoma, Non-Small-Cell Lung 287 Colorectal Neoplasms 159 Prostatic Neoplasms 158 Carcinoma, Hepatocellular 144 Neoplasms 137 Leukemia, Myeloid, Acute 131 Lung Neoplasms 117 Squamous Cell Carcinoma of Head and Neck 108 Multiple Myeloma 104 Triple Negative Breast Neoplasms 102 Recurrence 101 Pancreatic Neoplasms 96 Stomach Neoplasms 94 Ovarian Neoplasms 89 Neoplasm Metastasis 87 Lymphoma, Large B-Cell, Diffuse 81 Sarcoma 70 Esophageal Neoplasms 68 Uterine Cervical Neoplasms 67 Precursor Cell Lymphoblastic Leukemia-Lymphoma 67 Melanoma 67 Brain Neoplasms 67 Rectal Neoplasms 64 Head and Neck Neoplasms 62 Glioblastoma 60 Carcinoma, Renal Cell 58 Myelodysplastic Syndromes 55 Lymphoma 55 Esophageal Squamous Cell Carcinoma 54

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Rare Tumor × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡